11 / 25
Page 55
Mater Sci Nanotechnol 2017 | Volume 1 Issue 2
allied
academies
Nanomaterials and Nanochemistry
November 29-30, 2017 | Atlanta, USA
International Conference on
R
NA interference and the therapeutic applications using
small interfering RNA was discovered more than 10 years
ago and currently is used in various applications including
cancer theragnostic. However, the research in this field
is still in its infancy. Many challenges like safe delivery of
targeted siRNA to nucleus and cytosol of cancerous cells
without compromising the activity of siRNA needs to be
addressed. We have overcome this hurdle with the help of
nanotechnology using PLGA hollow NPs (PLGAHNPs) and
suppressing the oncogene of MYC transcription factors by
using anti myc-siRNAs in human cancer cell lines. siRNA was
encapsulated in PLGAHNPs. PLGAHNPs of size 70 nmhad high
efficiency of gene release at pH 4.2 under in vitro conditions.
Cell penetrating peptide (CPP)- Tat peptide (TAT) and peptide
nucleic acid nucleolus localizing signal (PNA-NLS) was used
for siRNA delivery without interrupting the therapeutic
activity of siRNA. Incubation of the siRNA encapsulated
PLGAHNPs functionalized with TAT and PNA-NLS (TAT-siRNA-
PNA-PLGAHNPs-siRNA) with cancer cells resulted in reduced
cell proliferation. A downregulation of gene expression by
90%was observed even with low concentration of siRNA. We
found complete arrest of cell division which was mediated
by downregulation of MYC expression. Further we used the
combination of gold nanoparticles with PNANLS and siRNA
encapsulated in PLGAHNPs around the mean size diameter
of 100nm. The encapsulation efficiency of siRNA with AuNPs
is increased by 20% when compared to siRNA alone in
PLGAHNPs. The gene expression of MYC in cancer cells was
down regulated by 92%.
e:
araichur5@gmail.comRegime of gene silencing: Efficient siRNA delivery into cancer cells using nanocapsules
Archana Raichur
IIT-Delhi, India